Kymera Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -42.25M-46.42M-100.70M-161.43M-165.73M-261.88M
Depreciation and Depletion 0.80M1.80M2.40M3.00M3.60M7.40M
Share-based Compensation 1.20M5.19M24.97M35.48M43.12M55.01M
Gains from Sales and Divestitures 0.10M0.08M0.04M0.04M0.17M
Gains from Investment Securities 16.52M0.03M1.99M1.00M48.83M-0.17M
Asset Writedowns and Impairment 4.92M
Non-cash Items 7.80M314.00M1.93M3.51M49.62M6.20M
Cash from Operations 17.91M88.13M-128.95M-153.09M-102.83M-194.50M
Depreciation, Depletion & Amortization
Amortization of Deferred Charges 1.57M5.81M0.89M-5.23M-13.98M
Depreciation & Amortization (CF) 0.82M1.76M2.40M2.98M3.56M7.37M
Change in Working Capital
Change in Receivables 0.58M-0.58M
Change in Account Payables 0.90M0.99M0.05M0.25M2.04M-0.31M
Change in Accured Expenses 2.25M5.75M12.60M4.52M3.18M4.18M
Other Working Capital Changes 52.99M117.40M-69.36M-37.77M18.58M-41.08M
Investing Activities
Capital Expenditures 0.53M9.10M1.60M2.84M34.48M12.84M
Change in Acquisitions & Divestments 115.89M358.17M469.33M363.52M509.99M
Cash from Investing Activities -16.49M-422.59M-99.83M20.52M139.89M-404.08M
Financing Activities
Other financing activities 0.37M0.55M0.85M1.13M0.08M1.58M
Cash from Financing Activities 34.91M289.26M250.28M153.00M4.19M608.85M
Additional items
Change in Cash 36.33M-45.20M21.50M20.43M41.25M10.27M
Free Cash Flow 17.37M79.03M-130.54M-155.92M-137.31M-207.34M
Net Cash Flow 36.33M-45.20M21.50M20.43M41.25M10.27M